Entering text into the input field will update the search result below

Data readout on AstraZeneca's late-stage lung cancer study of durvalumab extended to November

Apr. 26, 2017 12:27 PM ETAstraZeneca PLC (AZN) StockAZNBy: Douglas W. House, SA News Editor1 Comment
  • Top-line results from AstraZeneca's (AZN +0.1%) Phase 3 clinical trial, ARCTIC, assessing durvalumab (MEDI4736) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) are now expected in mid-November instead of late Q2. A spokesperson says the delay is due to the number of observed clinical events not yet reaching the protocol target.
  • ARCTIC is evaluating durvalumab as monotherapy or in combination with tremelimumab in NSCLC patients who have received at least two prior lines of platinum-based chemo.
  • Durvalumab is a PD-L1 inhibitor and tremelimumab is CTLA-4 inhibitor. Almost three months ago, the company terminated late-stage development of the combo in metastatic pancreatic ductal carcinoma.
  • Previously: AstraZeneca bails on late-stage cancer combo in pancreatic cancer (Feb. 3)

Recommended For You

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC